Comparing the current results to its competitors, Protalix Biotherapeutics Inc reported Revenue increase in the 1 quarter 2026 by 233.73 % year on year, while most of its competitors have experienced contraction in revenues by -36.45 %, achieved in the same quarter.
Protalix Biotherapeutics Inc 's Comment on Competition and Industry Peers
The company competes in the treatment of Gaucher disease primarily with enzyme replacement therapies Cerezyme, marketed by Sanofi Genzyme, and Vpriv, marketed by Takeda (formerly Shire). Actelion also markets Zavesca (miglustat), a small molecule drug for mild to moderate Type 1 Gaucher disease. The competitive environment includes academic institutions, governmental agencies, and other public and private research organizations engaged in research and patent activities that may lead to competing products or technologies. Acquisitions of competing companies by large pharmaceutical or biotechnology firms may increase competitors' resources. The company aims to maintain its competitive position through intellectual property rights, patent filings in multiple jurisdictions, proprietary know-how, technological innovation, licensing, and partnerships.
Due to outstanding performance in Overall company, revenue grew by 233.73 % Protalix Biotherapeutics inc improved its market share, to approximately 9.16 %.
Publicly Traded Peers of Protalix Biotherapeutics inc
Taysha Gene Therapies Inc Share Performance
-4.34%
This Quarter
Taysha Gene Therapies Inc
Profile
Taysha Gene Therapies Inc operates under a business model focused on developing and commercializing innovative genetic therapies to treat and potentially cure patients with rare monogenic diseases. Utilizing cutting-edge technologies, the company aims to bring transformative treatments to market in order to improve the lives of individuals suffering from these rare genetic disorders.
CRISPR Therapeutics AG is a biopharmaceutical company focused on developing transformative gene-based medicines using its CRISPR/Cas9 gene-editing platform. They aim to leverage the potential of CRISPR to treat severe genetic diseases by directly modifying genes within the body's cells. The company collaborates with partners, conducts research and development of their therapeutics, and ultimately aims to bring their innovative treatments to market.
Cargo Therapeutics Inc is a biotechnology company that utilizes a unique business model focused on developing targeted therapeutics. Their approach involves engineering cell-penetrating peptides to deliver various cargoes, such as gene therapies or small molecules, directly to specific cells or tissues, increasing precision and effectiveness of treatments. By leveraging this technology, the company aims to address unmet medical needs with potentially transformative therapies.
Sana Biotechnology Inc operates as a biotechnology company that focuses on developing and commercializing cellular therapies for various diseases. Their business model involves leveraging innovative technologies and collaborations with clinical and industry partners to develop advanced medical treatments.
Sources:
Protalix Biotherapeutics inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Protalix Biotherapeutics inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
